ArticleJournal of neuro-oncology2013
MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Susceptibility- and T2*-weighted MRI features of CNS large B-cell lymphoma in a large single-center cohort: prevalence, patterns, and clinical associations.Journal of neuro-oncology · 2025Article
- Multiparametric MRI for differential diagnosis of primary central nervous system lymphoma and atypical glioblastoma: an analysis incorporating DWI, DCE-MRI, and contrast agent preload DSC-PWI.BMC medical imaging · 2025Article
- Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lymphoma.Brain tumor pathology · 2024Article
- Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria.Discover oncology · 2024Article
- Article
- Primary central nervous system lymphoma (PCNSL) mimicking a falx meningioma with increasingly massive intracerebral hemorrhage.Radiology case reports · 2023Article
- Differentiation of malignant brain tumor types using intratumoral and peritumoral radiomic features.Frontiers in oncology · 2022Article
- Delayed Contrast Enhancement in Magnetic Resonance Imaging and Vascular Morphology of Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?Neuroradiology · 2018Article
- Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.BioMed research international · 2018Review
- Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Contrast media & molecular imaging · 2017Review
- Alterations of the Blood-Brain Barrier and Regional Perfusion in Tumor Development: MRI Insights from a Rat C6 Glioma Model.PloS one · 2016Article
- Article
- [Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].Der Nervenarzt · 2014Article
- Microstructural differentiation of cerebral metastases, glioblastoma, meningioma, and primary CNS lymphoma using advanced diffusion imaging techniques.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse cerebral infiltration of primary brain tumors may be missed on conventional MRI. In glioblastomas it may be visible on MR-perfusion images as an elevated rCBV adjacent to the contrast enhancing area (penumbra). We aimed to evaluate whether penumbral rCBV of primary central nervous system lymphomas (PCNSL) is also increased and if PCNSL perfusion has different features than that of glioblastomas. We measured dynamic susceptibility contrast MR-perfusion at 3 Tesla in 38 presurgical patients with histopathological diagnosis of PCNSL (n = 19) and glioblastoma (n = 19). We compared normalized rCBV within and adjacent to the enhancing area and evaluated time-signal intensity curves (TSIC) in all patients. Histopathological comparison of patients with different TSIC patterns (with or without shoulder-like increase) was performed. Relative to the normal tissue, rCBV within and adjacent to the enhancing area was increased (p < 0.05) in both glioblastomas and PCNSL. In the penumbra the increase was moderate in both groups, with 1.4 ± 0.46 in PCNSL and 1.82 ± 0.82 in glioblastomas (p = 0.07 between groups). In the enhancing tumor the increase was moderate in PCNSL (1.46 ± 0.62) and marked in glioblastomas (4.13 ± 2.44) (p < 0.001 between groups). A shoulder-like TSIC increase was exclusively found in PCNSL (11/19) and was significantly associated with a less prominent reticulin fibre network compared to the PCNSL without a shoulder-like TSIC increase. The moderately increased penumbral rCBV in PCNSL and glioblastomas reveals tumor-related changes beyond the tumor borders which are invisible with conventional MRI. PCNSL can be differentiated from glioblastomas through their significantly lower rCBV and shoulder-like signal intensity changes inside the enhancing area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.